iiinova — where your digital self keeps evolving

shipam.bsky.social

@shipam.bsky.social

Reposted by @shipam.bsky.social

mikeehrenstein.bsky.social @mikeehrenstein.bsky.social · 17/10/2025

Just out! We challenge the prevailing caution and advocate for a biomarker-guided approach soon to be tested in the STRATIFY lupus trial: Rituximab–belimumab combination for refractory SLE @shipam.bsky.social @versusarthritis.bsky.social www.thelancet.com/journals/lan...

thelancet.com

Revisiting safety and refining benefit of rituximab–belimumab combination for refractory SLE

B-cell depletion using rituximab is used to treat systemic lupus erythematosus (SLE), particularly for patients whose disease is refractory to conventional immunosuppressants (eg, mycophenolate), and ...

042

shipam.bsky.social @shipam.bsky.social · 23/07/2025

@arrdept-ucldom.bsky.social Just out! Our latest lupus paper shows IgA2⁺ B-cells & IgA2-anti-dsDNA Abs are selectively targeted doi.org/10.1016/j.xc... Builds on theranostic discovery doi.org/10.1016/S266... On BEAT-Lupus doi.org/10.7326/M21-... Lupus ≠ one-size-fits-all doi.org/10.1084/jem....

082

Reposted by @shipam.bsky.social

mikeehrenstein.bsky.social @mikeehrenstein.bsky.social · 28/03/2025

STRATIFY lupus is a newly funded precision medicine biomarker enrichment trial funded by @versusarthritis.bsky.social and @nihr.bsky.social with support from @glaxosmithkline.bsky.social in collaboration with @shipam.bsky.social & many UK lupus specialist centres. Will start recruitment early 2026.

042